Durvalumab

Where the papers sit

22 papers from the last 6 months study durvalumab directly · updated from PubMed 8 Oct 2026

• Hepatocellular Carcinoma Immunotherapy

  Dual checkpoint blockade with durvalumab-tremelimumab is being compared with atezolizumab-bevacizumab and lenvatinib-based strategies in unresectable hepatocellular carcinoma. Real-world cohorts and indirect comparisons focus on progression-free and overall survival, response patterns, and treatment sequencing. DCP and pretreatment CD8+ T-cell numbers recur as candidate markers of differential benefit. Trials are extending combinations into transarterial chemoembolisation and hepatic arterial infusion chemotherapy, while the optimal sequence remains open.

  8 papers · 36.4%

• Thoracic Cancer Immunotherapy

  Durvalumab is being tested across EGFR-mutated NSCLC, small-cell lung cancer and neuroendocrine thoracic tumours, with progression-free survival and response as recurring endpoints. Multi-omics and pharmacokinetic analyses seek benefit-enriched subgroups and exposure targets, while EGFR status is examined as a recurrence marker. Combination strategies include platinum-etoposide and ceralasertib, but evidence spans disparate settings. Nephrotic syndrome and organizing pneumonia underscore unresolved toxicity.

  7 papers · 31.8%

• Immunotherapy and Survival Outcomes

  Perioperative durvalumab is being assessed in cisplatin-eligible muscle-invasive bladder cancer, with event-free survival and cure fraction as key endpoints. NIAGARA reanalyses use reconstructed patient data and mixture-cure models to quantify durable benefit beyond conventional hazard ratios. Neoadjuvant durvalumab with or without tremelimumab is being paired with dose-dense MVAC, testing whether intensified checkpoint blockade improves outcomes. A separate biliary-tract analysis uses the albumin-bilirubin score to refine prognosis, leaving the cluster clinically broad.

  4 papers · 18.2%

• Perioperative Immunotherapy in Cancer

  Perioperative durvalumab is being combined with chemotherapy for triple-negative breast cancer and resectable gastric or gastro-oesophageal junction cancer. Breast-cancer studies test paclitaxel with or without capivasertib or oleclumab, while gastric regimens pair durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel. Long-term analyses keep pathologic response, event-free survival and safety central. PD-L1 or CD274-linked selection and the durability of benefit remain unresolved.

  3 papers · 13.6%